This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jakubowska, A. Articles by Hamann, U. Search for Related Content PubMed PubMed Citation Articles by Jakubowska, A. Articles by Hamann, U.

The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers

Departments of ¹ Genetics and Pathology, and ² Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland; ³ Division of Molecular Genome Analysis and ⁴ Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany; and ⁵ Discipline of Medical Genetics, School of Biomedical Sciences, University of Newcastle, and The Hunter Medical Research Institute, Newcastle, New South Wales, Australia

Requests for reprints: Anna Jakubowska, Department of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 70-115 Szczecin, Poland. Phone: 48-91-48-22-15-32; Fax: 48-91-48-22-15-33. E-mail: aniaj{at}sci.pam.szczecin.pl

Breast and ovarian cancer penetrance in BRCA1 mutation carriers is estimated to be between 15% and 80% by age 70 years. At present, it is not possible to predict with any certainty who is most likely to develop disease or which age it will develop. Previous studies have tried to correlate the sites of BRCA1 mutations with disease risk; however, the results have not yielded any definitive association. An alternative explanation that could account for differences in the penetrance of BRCA1 mutations is the action of modifier genes. In this study, we have investigated the role of the RAD51_135_G>C polymorphism in breast and ovarian cancer case-control populations of Polish women who have been matched for BRCA1 mutation and year of birth. The results reveal that women who harbor the C allele have almost twice the reduction in breast and ovarian cancer risk compared with women who harbor only the G allele. These findings suggest that the effect of the RAD51 C allele is an important risk modifier for malignancies occurring on a background of BRCA1 mutations. In addition, we were able to show that the site of the BRCA1 mutation does not influence the effect of the RAD51 C allele, indicating that this polymorphism contributes to prevention of disease in BRCA1 carriers. In conclusion, the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations. (Cancer Epidemiol Biomarkers Prev 2007;16(2):270–5)

This article has been cited by other articles:

				J. Brooks, R. E. Shore, A. Zeleniuch-Jacquotte, D. Currie, Y. Afanasyeva, K. L. Koenig, A. A. Arslan, P. Toniolo, and I. Wirgin Polymorphisms in RAD51, XRCC2, and XRCC3 Are Not Related to Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 1016 - 1019. [Full Text] [PDF]